Catalyst Event

CSPC Pharmaceutical Group Ltd (1093) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

4/24/2026, 12:00:00 AM

OtherSentiment: Positive

Announced on 2026-04-24 that its high-selectivity KAT6 inhibitor (SYH2095 tablet) received FDA IND approval; a ~1% price impact is estimated as this is an early-stage regulatory milestone.

Korean Translation

2026년 4월 24일, 고선택성 KAT6 억제제(SYH2095정)가 미국 FDA로부터 임상시험계획(IND) 승인을 받았다고 발표함. 초기 단계 마일스톤 달성으로 약 1%의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline